Literature DB >> 7680297

Antigenic regions within the hepatitis C virus envelope 1 and non-structural proteins: identification of an IgG3-restricted recognition site with the envelope 1 protein.

M Sällberg1, U Rudén, B Wahren, L O Magnius.   

Abstract

Antibody binding to antigenic regions of hepatitis C virus (HCV) envelope 1 (E1; residues 183-380, E2/non-structural (NS) 1 (residues 380-437), NS1 (residues 643-690), and NS4 (1684-1751) proteins were assayed for 50 sera with antibodies to HCV (anti-HCV) and for 46 sera without anti-HCV. Thirty-four peptides, 18 residues long with an eight-amino acid overlap within each HCV region, were synthesized and tested with all 96 sera. Within the E region 183-380, the major binding site was located to residues 203-220, and was recognized by eight sera. Within the E2/NS1 region 380-437, the peptide covering residues 410-427 was recognized by two sera, and within the NS1 region 643-690, peptides covering residues 663-690 were recognized by four sera. Within the NS4 region 1684-1751, 27 sera were reactive to one or more of the NS4 peptides, and 21 out of these were reactive with peptide 1694-1711. One part of the major binding site could be located to residues 1701-1704, with the sequence Leu-Tyr-Arg-Glu. The IgG1, IgG3 and IgG4 subclasses were reactive with the five antigenic regions of HCV core, residues 1-18, 11-28, 21-38, 51-68 and 101-118. Reactivity to the major envelope site consisted almost exclusively of IgG3, and reactivity to the major site of NS4 consisted only of IgG1. Thus, a non-restricted IgG response to linear HCV-encoded binding sites was found to the core protein, whereas IgG subclass-restricted linear binding sites were found within the E1 protein, and within the NS4 protein.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7680297      PMCID: PMC1554722          DOI: 10.1111/j.1365-2249.1993.tb05929.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  IgG subclasses of anti-HBs antibodies in vaccinated and nonvaccinated individuals and in anti-HBs immunoglobulin preparations.

Authors:  F Skvaril; H Joller-Jemelka
Journal:  Int Arch Allergy Appl Immunol       Date:  1984

2.  Human and murine B-cells recognize the HBeAg/beta (or HBe2) epitope as a linear determinant.

Authors:  M Sällberg; U Rudén; B Wahren; M Noah; L O Magnius
Journal:  Mol Immunol       Date:  1991-07       Impact factor: 4.407

3.  Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay.

Authors:  C L Van der Poel; H T Cuypers; H W Reesink; A J Weiner; S Quan; R Di Nello; J J Van Boven; I Winkel; D Mulder-Folkerts; P J Exel-Oehlers
Journal:  Lancet       Date:  1991-02-09       Impact factor: 79.321

4.  Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins.

Authors:  A J Weiner; M J Brauer; J Rosenblatt; K H Richman; J Tung; K Crawford; F Bonino; G Saracco; Q L Choo; M Houghton
Journal:  Virology       Date:  1991-02       Impact factor: 3.616

5.  Genetic organization and diversity of the hepatitis C virus.

Authors:  Q L Choo; K H Richman; J H Han; K Berger; C Lee; C Dong; C Gallegos; D Coit; R Medina-Selby; P J Barr
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

6.  Serodiagnosis of hepatitis C virus (HCV) infection with an HCV core protein molecularly expressed by a recombinant baculovirus.

Authors:  J Chiba; H Ohba; Y Matsuura; Y Watanabe; T Katayama; S Kikuchi; I Saito; T Miyamura
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

7.  Lack of protective immunity against reinfection with hepatitis C virus.

Authors:  P Farci; H J Alter; S Govindarajan; D C Wong; R Engle; R R Lesniewski; I K Mushahwar; S M Desai; R H Miller; N Ogata
Journal:  Science       Date:  1992-10-02       Impact factor: 47.728

8.  Immunoglobulin isotypes of anti-HBc and anti-HBe and hepatitis B virus (HBV) DNA elimination in acute hepatitis B.

Authors:  M Sälberg; H Norder; O Weiland; L Magnius
Journal:  J Med Virol       Date:  1989-12       Impact factor: 2.327

9.  Comparison of class and subclass distribution of antibodies to the hepatitis B core and B e antigens in chronic hepatitis B.

Authors:  M Sällberg; H Norder; L O Magnius
Journal:  J Med Virol       Date:  1990-01       Impact factor: 2.327

10.  Detection of hepatitis C virus infection by enzyme-linked immunosorbent assay system using core protein expressed in Escherichia coli.

Authors:  K Muraiso; M Hijikata; N Kato; K Shimotohno; N Okazaki; S Ohkoshi; M Uura; S Kaneko; K Kobayashi; M Omata
Journal:  Jpn J Cancer Res       Date:  1991-08
View more
  11 in total

1.  Clustering of rare peptide segments in the HCV immunome.

Authors:  Angela Stufano; Giovanni Capone; Barbara Pesetti; Lorenzo Polimeno; Darja Kanduc
Journal:  Self Nonself       Date:  2010-02-03

2.  Antibody production against hepatitis C virus core and nonstructural 3 proteins is highly sensitive to deficits in T-cell function.

Authors:  Y Ando; A Sönnerborg; L Barkholt; A Birkett; B G Ericzon; M Sällberg
Journal:  Clin Diagn Lab Immunol       Date:  1997-01

3.  The association of complement activation at a low temperature with hepatitis C virus infection in comparison with cryoglobulin.

Authors:  K Ueda; H Nakajima; T Nakagawa; A Shimizu
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

4.  Human monoclonal antibodies for the immunological characterization of a highly conserved protein domain of the hepatitis C virus glycoprotein E1.

Authors:  K Siemoneit; M da S Cardoso; K Koerner; A Wölpl; B Kubanek
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

5.  Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus.

Authors:  Jean-Christophe Meunier; Rodney S Russell; Vera Goossens; Sofie Priem; Hugo Walter; Erik Depla; Ann Union; Kristina N Faulk; Jens Bukh; Suzanne U Emerson; Robert H Purcell
Journal:  J Virol       Date:  2007-10-31       Impact factor: 5.103

6.  Molecular basis for antibody cross-reactivity between the hepatitis C virus core protein and the host-derived GOR protein.

Authors:  Z X Zhang; M Chen; K Wallhagen; J Trojnar; L O Magnius; B Wahren; M Sällberg
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

7.  Antigenic structure of the complete nonstructural (NS) 2 and 5 proteins of hepatitis C virus (HCV): anti-HCV NS2 and NS5 antibody reactivities in relation to HCV serotype, presence of HCV RNA, and acute HCV infection.

Authors:  Z X Zhang; M Chen; A Sönnerborg; M Sällberg
Journal:  Clin Diagn Lab Immunol       Date:  1994-05

8.  Antigenic structure of the hepatitis C virus envelope 2 protein.

Authors:  Z X Zhang; A Sönnerborg; M Sällberg
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

9.  Restricted isotypic antibody reactivity to hepatitis C virus synthetic peptides in immunocompromised patients.

Authors:  M Devesa; A de Saez; G León; F Sirit; C Cosson; H Bermúdez; F Liprandi; O Noya; F H Pujol
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

10.  Relationship between humoral response against hepatitis C virus and disease overcome.

Authors:  Carine Brakha; Philippe Arvers; Florent Villiers; Alice Marlu; Arnaud Buhot; Thierry Livache; Roberto Calemczuk; Jean-Pierre Zarski; Christian L Villiers; Patrice N Marche; Marie-Bernadette Villiers
Journal:  Springerplus       Date:  2014-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.